Clinical trial
Tipifarnib, Cytarabine, and Daunorubicin in Treating Older Patients With Acute…
NCT00101153 · University Health Network, Toronto, Other · Completed
Key facts
| NCT number | NCT00101153 |
|---|---|
| Title | Tipifarnib, Cytarabine, and Daunorubicin in Treating Older Patients With Acute Myeloid Leukemia |
| Official title | A Phase I Study Of Therapy With The Farnesyl Transferase Inhibitor R115777 (Zarnestra) Combined With Conventional Induction And Consolidation Chemotherapy For Previously Untreated Patients Over Age 55 With Acute Myeloid Leukemia (AML) |
| Lead sponsor | University Health Network, Toronto, Other |
| Collaborators | National Cancer Institute (NCI) NIH |
| Status | Completed |
| Phase | Phase 1 |
| Study type | Interventional |
| Conditions | Leukemia |
| Intervention type | Drug |
| Interventions | cytarabine, daunorubicin hydrochloride, tipifarnib |
| Enrollment | 24 |
| Start date | Apr 1, 2007 |
| Primary completion | Mar 1, 2010 |
| First posted | Jan 10, 2005 |
| Last update posted | Jul 23, 2015 |
| Countries | Canada |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: